Status:

RECRUITING

Semaglutide in Women With Polycystic Ovary Syndrome and Obesity

Lead Sponsor:

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Conditions:

Polycystic Ovary Syndrome (PCOS) Women

Obesity

Eligibility:

FEMALE

10-45 years

Phase:

PHASE2

PHASE3

Brief Summary

Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder that is frequently associated with metabolic features, including obesity. Improvement of metabolic manifestations helps in the control o...

Detailed Description

Introduction Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder, impacting approximately 10-20% of women in their reproductive years. The syndrome is typically characterized by reprodu...

Eligibility Criteria

Inclusion

  • Reproductive-aged women with PCOS diagnosed according to International evidence based guidelines 2023 and obesity

Exclusion

  • Having DM, other significant systemic diseases- chronic kidney disease (eGFR \<60mL/minute/ 1.73 m2 BSA), chronic liver disease (ALT \>3 × ULN), and heart failure
  • Patients having PCOS mimicking endocrine disorders (untreated thyroid dysfunctions, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's syndrome, acromegaly, hypothalamic disorder etc.)
  • Those taking any other weight loss medications (eg., orlistat, liraglutide) within the last 3 months
  • Those who have undergone bariatric surgery
  • Any conditions causing weight loss (thyrotoxicosis, Addison's disease, chronic infection, connective tissue disorder, cancer, etc)
  • Secondary causes of obesity (major mood disorders, steroids, valproate, oral contraceptives, etc)
  • Contraindications for semaglutide: personal or family history of medullary carcinoma of the thyroid, history of acute pancreatitis, gallbladder disease
  • Planning for pregnancy or current pregnancy/ lactation

Key Trial Info

Start Date :

February 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT06896981

Start Date

February 1 2025

End Date

December 31 2025

Last Update

April 2 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University

Dhaka, Dhaka Division, Bangladesh, 1000